<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466086</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6013</org_study_id>
    <nct_id>NCT03466086</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients</brief_title>
  <official_title>Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a randomized, double-masked, cross-over, bilateral, 2 treatment x 2
      period, dispensing 4-visit study with a 7-9 day washout period in between visits 2 and 3. The
      study will last approximately 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Actual">May 16, 2018</completion_date>
  <primary_completion_date type="Actual">May 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Comfort</measure>
    <time_frame>1-Week Follow-up</time_frame>
    <description>Ocular comfort was measured using the visual analogue scale of 0 to 100. Where 0 is extremely uncomfortable and 100 is extremely comfortable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Dryness Rating</measure>
    <time_frame>1-Week Follow-up</time_frame>
    <description>Subjective dryness was assessed using Ocular Surface Disease Index (OSDI©) instrument. Dryness is evaluated on a scale of 0 to 100, where higher scores indicate more symptoms of dryness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Test/Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Eye Drops</intervention_name>
    <description>blink® intensive TRIPLE ACTION 3 in 1 eye drops</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Eye Drops</intervention_name>
    <description>Systane® BALANCE eye drops</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potential subjects must satisfy all the following criteria to be enrolled in the
             study:

               1. Subjects must be at least 18 years of age and no more than 69 years of age
                  (inclusive)

               2. Subjects must be non-contact lens wearers

               3. Subjects must have a DEQ-5 score of &gt;6 at either Visit 0 (pre-screen) and/or
                  Visit 1 (screening).

               4. Subjects must achieve visual acuity of 20/30 (equivalent to 0.18 logMAR) or
                  better in each eye, either unaided or best corrected.

               5. Subjects must possess a functional/usable pair of spectacles and bring them to
                  every visit (only if applicable - to the investigators discretion).

               6. Subjects must read, understand, and sign the Statement of Informed Consent.

               7. Subjects must appear able and willing to adhere to the instructions set forth in
                  this clinical protocol

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Currently pregnant or breast-feeding.

               2. Diabetes.

               3. Any ocular or systemic allergies or disease which may interfere with the clinical
                  trial (at the investigator's discretion).

               4. Any systemic disease, autoimmune disease, or use of medication which may
                  interfere with the clinical trial (at the investigator's discretion).

               5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious
                  immunosuppressive disease (e.g. HIV), by self-report

               6. Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema,
                  corneal staining, corneal vascularization, conjunctival injection, tarsal
                  abnormalities, bulbar injection) on the FDA scale

               7. Any active ocular abnormalities/conditions that may interfere with the clinical
                  trial (this includes, but not limited to, chalazia, recurrent styles, pterygium,
                  infection, etc)

               8. Any corneal distortion due to previous rigid gas permeable lens wear, surgery or
                  pathology

               9. History of any ocular or corneal surgery (e.g. RK, PRK, LASIK)

              10. Participation in any pharmaceutical or medical device related clinical trial
                  within 14 days prior to study enrollment.

              11. History of binocular vision abnormality or strabismus.

              12. Habitual wearers of soft contact lenses in the past 1 month or rigid gas
                  permeable lens within the past 3 months

              13. Current habitual use of Prescription Only Medicines (POM) to treat dry eye or
                  ocular discomfort, ocular steroids, or any medication (RX or OTC) that would
                  interfere with the clinical study (at the discretion of the investigator).)

              14. Employees of investigational clinic (investigator, coordinator, and technician
                  etc) or family member of an employee of the clinical site by self-report.

        In addition to the above criteria, patients with any allergy or sensitivity to ingredients
        that this product may contain (liposomes, sodium hyaluronate, vitamin E polyethylene glycol
        succinate (TPGS), polyethylene glycol 400 (PEG 400), disodium edetate, polyhexanide
        methylbiguanide, propylene glycol, boric acid, dimyristoyl phosphatidylglycerol, edetate
        disodium, hydroxypropyl guar, mineral oil, polyoxyl 40 sterate, polyquaternium-1, sorbitan
        tristearate, sorbitol, hydrochloric acid and/or sodium hydroxide) should not participate in
        the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <results_first_submitted>May 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03466086/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 57 subjects were enrolled in this study, of which 55 subjects were assigned to receive at least 1 eye drop while, 2 subjects were screen failures and/or not assigned. Of the total assigned subjects, 53 subjects completed the study and 2 subjects discontinued the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Test/Control</title>
          <description>Subjects randomized to this sequence received the Test eye drop during the first period and then received the Control eye drop during the second period.</description>
        </group>
        <group group_id="P2">
          <title>Control/Test</title>
          <description>Subjects randomized to this sequence received the Control eye drop during the first period and then received the Test eye drop during the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor decision due to study timeline</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dispensed Subjects</title>
          <description>All subjects dispensed at least one eye drop and 1 contact lens</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.76" spread="11.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Comfort</title>
        <description>Ocular comfort was measured using the visual analogue scale of 0 to 100. Where 0 is extremely uncomfortable and 100 is extremely comfortable.</description>
        <time_frame>1-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>All subjects that wore the Test eye drop during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>All subjects that wore the control eye drop in either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Comfort</title>
          <description>Ocular comfort was measured using the visual analogue scale of 0 to 100. Where 0 is extremely uncomfortable and 100 is extremely comfortable.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.96" spread="12.407"/>
                    <measurement group_id="O2" value="82.49" spread="15.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was a pilot study and the sample size was not based on any empirical power calculation.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.238</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.35</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
            <estimate_desc>Mean Difference was calculated as Test minus Control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Dryness Rating</title>
        <description>Subjective dryness was assessed using Ocular Surface Disease Index (OSDI©) instrument. Dryness is evaluated on a scale of 0 to 100, where higher scores indicate more symptoms of dryness</description>
        <time_frame>1-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>All subjects that wore the Test eye drop during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>All subjects that wore the control eye drop in either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Dryness Rating</title>
          <description>Subjective dryness was assessed using Ocular Surface Disease Index (OSDI©) instrument. Dryness is evaluated on a scale of 0 to 100, where higher scores indicate more symptoms of dryness</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.68" spread="10.162"/>
                    <measurement group_id="O2" value="24.69" spread="10.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was a pilot study and the sample size was not based on any empirical power calculation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority will be declared if the lower bound of the 2-sided 95% credible interval of the difference between Test and Control is less than 0.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.951</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
            <other_analysis_desc>Mean difference was calculated as Test - Control</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 3 week per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>All subjects that wore the Test eye drop during either period 1 or period 2 during the study.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>All subjects that wore the Control eye drop during either period 1 or period 2 during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Meredith Bishop, OD, MS, FAAO</name_or_title>
      <organization>Johnson &amp; Johnson Vision</organization>
      <phone>904-443-1396</phone>
      <email>MBishop4@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

